Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
Axovant Sciences today announced that its chief executive Officer David Hung has resigned to pursue other opportunities and has also resigned from the company’s board of directors. 12 February 2018
Oxford, UK-based biotech Immunocore, the soluble TCR company developing first-in-class biologics that have the potential to transform patient lives, has announced that Dr Eliot Forster has stepped down as chief executive. 12 February 2018
As the US Centers for Disease Control and Prevention (CDC) struggles to manage the country’s worst flu outbreak in years, the agency suffered a blow Wednesday with the resignation of its director Brenda Fitzgerald. 2 February 2018
Danish diabetes giant Novo Nordisk took a 6% hit in the stock market on Thursday morning after announcing results from the fourth quarter of 2017 along with the full-year figures. 1 February 2018
Following the departure of Christophe Bourdon in December, US drugmaker Alexion Pharmaceuticals has named his replacement in the role of senior vice president and head of Europe/Middle East/Africa/Canada (EMEAC). 30 January 2018
A long-standing leader in health technology assessment (HTA) in the UK and internationally has taken a step across the divide to become a leading lobbyist for pharma. 25 January 2018
Belgian biotech firm Ablynx today announced the appointment of Robert Friesen as chief scientific officer (CSO), effective March 1, 2018. 24 January 2018
Merck & Co UK unit MSD has today announced the appointment of Dr Fiona Marshall to lead its new discovery research facility in London, focused on early bioscience discovery and entrepreneurial innovation. 22 January 2018
Japanese GPCR medicines specialist Sosei Group today announced that Dr Fiona Marshall has resigned from her position as executive vice president and chief scientific officer of Sosei to assume a senior role outside the company. 19 January 2018
Jordan-headquartered Hikma Pharmaceuticals today announced that Surendera Tyagi will join the company as group chief scientific officer and global head of R&D. 15 January 2018
Novartis today revealed that Elizabeth (Liz) Barrett, currently global president oncology at Pfizer, will join the company as chief executive of Novartis Oncology and a member of the executive committee of Novartis, effective February 1, 2018 11 January 2018
French drugmaker Ipsen today announced the promotion of Dr Aidan Murphy as executive vice president, technical operations, effective January 1, 2018. 10 January 2018
Dr Peter Fellner, who has served as chairman of Belgian biotech firm Ablynx since 2013, has decided to resign from the board with immediate effect. 9 January 2018
US biotech Neurocrine Biosciences has named an experienced Eli Lilly executive its new chief medical officer after Christopher O'Brien announced that he would be retiring. 8 January 2018
Ophthalmic drug specialist Aerie Pharmaceuticals has appointed Julia Williams as director of medical affairs, initially focused on the launch of Rhopressa (netarsudil ophthalmic solution) 0.02%. 3 January 2018